← All trials
NCT02595970
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2015
- Primary completion
- Feb 9, 2017
- Completion date
- Feb 9, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 120
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- NovartisLead sponsor
- HOPITAL PRIVE D'ANTONY - ANTONYOverall official - principal investigator
- CH VICTOR DUPOUY - ARGENTEUILOverall official - principal investigator
- CABINET BATEAU BLANC - MARTIGUESOverall official - principal investigator
- HIA SAINTE ANNE - TOULONOverall official - principal investigator
- HOPITAL LARREY - TOULOUSEOverall official - principal investigator
- HIA LEGOUEST - METZOverall official - principal investigator
- University of LimogesOverall official - principal investigator
- University of Nice Sophia AntipolisOverall official - principal investigator
- University of Picardie Jules VerneOverall official - principal investigator
- University of Western BrittanyOverall official - principal investigator
- Aix-University of MarseilleOverall official - principal investigator
- Rouen Normandy UniversityOverall official - principal investigator
- University of ParisOverall official - principal investigator
- Centre Hospitalier le MansOverall official - principal investigator
- Hopital Saint AndreOverall official - principal investigator
- Paris Diderot UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.